IRIS
SARACINO, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.671
EU - Europa 1.940
AS - Asia 806
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 3
OC - Oceania 2
Totale 12.434
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.664
SE - Svezia 589
CN - Cina 581
IT - Italia 409
DE - Germania 273
UA - Ucraina 162
FI - Finlandia 149
GB - Regno Unito 131
SG - Singapore 110
VN - Vietnam 68
FR - Francia 58
BE - Belgio 41
RU - Federazione Russa 41
IE - Irlanda 23
IN - India 23
CZ - Repubblica Ceca 22
HR - Croazia 11
CA - Canada 6
GR - Grecia 6
PK - Pakistan 6
CH - Svizzera 5
ID - Indonesia 5
PL - Polonia 5
ZA - Sudafrica 5
EU - Europa 4
AT - Austria 3
HK - Hong Kong 3
HU - Ungheria 3
KE - Kenya 3
NL - Olanda 3
PH - Filippine 3
AU - Australia 2
BR - Brasile 2
IL - Israele 2
CR - Costa Rica 1
ES - Italia 1
IR - Iran 1
JP - Giappone 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
Totale 12.434
Salva come PNG Salva come JPEG
Città #
Fairfield 1.607
Woodbridge 1.072
Ashburn 835
Houston 768
Chandler 721
Seattle 672
Cambridge 542
Wilmington 524
Ann Arbor 490
Nyköping 481
Jacksonville 399
Lawrence 182
Roxbury 179
Nanjing 176
New York 166
Beijing 138
Des Moines 104
Princeton 88
Bari 85
Singapore 72
Dong Ket 68
Inglewood 65
San Diego 61
Boardman 58
Hebei 41
Shenyang 37
Brooklyn 35
Brussels 35
Helsinki 35
Los Angeles 35
Nanchang 32
Jiaxing 29
London 28
Munich 28
Tianjin 25
Dearborn 24
Dublin 23
Milan 23
Rome 22
Paris 21
Brno 19
Pune 19
Falls Church 18
Taranto 18
Guangzhou 15
Modugno 13
Redwood City 12
Washington 12
Kilburn 10
Norwalk 10
Zagreb 10
Changsha 9
Bergamo 8
New Bedfont 7
Palermo 7
Hefei 6
Kunming 6
Marseille 6
Stockholm 6
Triggiano 6
Bologna 5
Indiana 5
Jinan 5
Magelang 5
Brescia 4
Edinburgh 4
Hounslow 4
Lahore 4
Mola Di Bari 4
San Francisco 4
Uster 4
Weimar 4
Zhengzhou 4
Amsterdam 3
Budapest 3
Chioggia 3
Chiswick 3
Clearwater 3
Detroit 3
Fort Worth 3
Grinzane Cavour 3
Hangzhou 3
Monmouth Junction 3
Montreal 3
Olomouc 3
Ravenna 3
Renton 3
Rosà 3
San Mateo 3
State College 3
Taizhou 3
Warsaw 3
Wuhan 3
Arnaia 2
Athens 2
Aversa 2
Bisceglie 2
Bitonto 2
Brindisi 2
Cape Town 2
Totale 10.373
Salva come PNG Salva come JPEG
Nome #
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 237
Economic evaluation of HIV treatments: The I.CO.N.A. cohort study 147
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 139
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 127
Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study 123
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 122
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 117
Co-receptor switch during HAART is independent of virological success 115
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 115
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 114
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 113
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 110
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 110
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 110
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study 106
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 105
Potential diagnostic properties of chest ultrasound in thoracic tuberculosis—A systematic review 105
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 104
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 103
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 101
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 101
A 75-year-old woman presenting with nasal vestibulitis 100
The elderly and direct antiviral agents: Constraint or challenge? 99
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. 99
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 99
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 97
An outbreak of HIV-1 BC recombinants in Southern Italy 96
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 96
Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique 95
Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010. 94
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 94
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 94
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 93
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 92
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 92
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 92
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 92
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 91
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients 89
The at risk child clinic (ARCC): 3 years of health activities in support of the most vulnerable children in Beira, Mozambique 89
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 88
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors 88
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients 88
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents 87
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 86
Epidemiological multicentric Italian society of infectious and tropical diseases study on prevalence of tropical diseases in hospitalized immigrants in Italy during 2002 86
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 86
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program 85
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 85
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 85
Evolution of antiretroviral prescription and response over a period of 8 years: An Italian multicentre observational prospective cohort study 84
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin 84
A 75-year-old woman presenting with nasal vestibulitis 84
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study 83
Splenic abscesses as a first manifestation of Crohn's disease: A case report 83
Tuberculosis and diabetes: Current state and future perspectives 82
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs? 82
Mortality in migrants living with HIV in western Europe (1997-2013): A collaborative cohort study 82
Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review 82
Reproductive choice in individuals HIV-1 infected in South Eastern Italy 82
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study 82
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 82
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 81
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 81
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? 80
Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe 80
Are the proposed env mutations actually associated with resistance to maraviroc? 80
Direct-acting antivirals for HIV/HCV co-infected individuals: as good as it gets? 79
null 79
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 79
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 79
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 79
null 78
Incidence of tuberculosis among HIV-Infected patients receiving highly active antiretroviral therapy in Europe and North America 78
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women 77
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 77
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 76
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 76
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. 75
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 75
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 74
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 74
Extended lamivudine treatment in patients affected by chronic active anti-Hbe positive hepatitis 73
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 73
Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study 73
null 72
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study 72
Impact of Ebola outbreak on reproductive health services in a rural district of Sierra Leone: A prospective observational study 72
Simit epidemiological multicentric study on hospitalized immigrants in Italy during 2002 71
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 71
Drug Resistance Mutations and Newly Recognized Treatment-Related Substitutions in the HIV-1 Protease Gene: Prevalence and Associations With Drug Exposure and Real or Virtual Phenotypic Resistance to Protease Inhibitors in Two Clinical Cohorts of Antiretroviral Experienced Patients 70
X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process. 69
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance and Herpesvirus Reactivation: A Double Face of Janus? 69
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients 69
Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A “turning-off” effect of liver inflammation? 68
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. 67
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 67
Letter: chronic hepatitis C genotype 3 infection - still a hurdle toward a direct-acting anti-viral-induced HCV cure? 67
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 67
null 66
Totale 8.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.104
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.306 0 177 102 336 445 254 343 401 473 322 321 132
2020/20212.394 157 268 155 277 334 119 240 170 175 246 97 156
2021/20221.320 86 158 21 61 53 109 81 91 86 96 183 295
2022/20232.120 320 210 153 145 229 296 42 290 314 17 58 46
2023/20241.181 81 227 72 89 115 276 39 44 31 37 41 129
2024/2025196 131 65 0 0 0 0 0 0 0 0 0 0
Totale 13.285